Rezul'taty klinicheskikh ispytaniy preparatov INGN 201 i genditsina, nesushchikh gen r53

References

[1] Read A., Strachan Т. Cancer Genetics. In: Human molecular genetics. 2nd ed. New York: Wiley; 1ЭЭЭ. p. 427-44.

[2] Lin L, Ye Y., Zakeri Z. p53, Apaf-1, caspase-3, and -Э are dispensable for Cdk5 activation during cell death. Cell Death and Differentiation 2006: 13; 141-50.

[3] Zuckerman V., Wolyniec K., Sionov R.V., Haupt S., Haupt Y. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J. Pathol. 2009; 219(1): 3-15.

[4] Chomchai J.S., DuW., SarkarF.H. et al. Prognostic significance of p53 gene mutations in laryngeal cancer. Laryngoscope 1999; 109(3): 455-9.

[5] Zhang S., Li Y., Li L. et al. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia. J. Oral Maxillofac. Surg. 2009; 67: 1074-82.

[6] Han D.M., Swisher S.G., Roth J.A., Komaki R. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 [INGN 201) and radiation therapy. Clin. Cancer Res. 2003; 9: 93.

[7] Yoo G.H., Moon J., LeBlanc M. et al. Phase II trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx. Arch. Otolaryngol. Head Neck Surg. 2009; 135(9): 869-74.

[8] Vokes E.E., Weichselbaum R.R., Lippman S.M., Hong W.K. Head and neck cancer. N. Engl. J. Med. 1993; 328(3): 184-94.

RIGHTS & PERMISSIONS

Eco-Vector